GLP-1 Weight Loss: What Healthcare Providers Need to Know

Key Takeaways

GLP-1 weight loss medications are all over the news, and nearly 15% of Americans have tried them out. But these medications aren’t a magic bullet for weight loss—healthcare providers need to evaluate each patient carefully to set expectations and avoid complications. Here’s what you need to know when prescribing and managing GLP-1s.  

Recommended courses: Expanding the GLP Landscape, Implicit and Explicit Bias Reduction Training in Healthcare, Acid Reflux: More Than Just Heartburn, Pharmacological Foundations: Diabetes Medications

We’re hearing more about glucagon-like peptide-1 (GLP-1) receptor agonists every day, and more than 1 in 7 Americans has been given a prescription. With popular brands boasting near-miraculous results, health professionals are being bombarded with questions by eager patients—and the answers can be extremely complicated.  

Anytime medications start trending, it’s critical for the workforce to get informed as quickly as possible. Courses like Expanding the GLP Landscape are vital resources that provide clarity, current research, and best practices.

What should every healthcare pro know about GLP-1 weight loss medications today? Here’s a rundown of the latest information.  

Understanding GLP-1 Medications

GLP-1 is a hormone in the small intestine that helps regulate insulin, blood sugar levels, digestion speed, and satiety. GLP-1 medications mimic this hormone, leading to lower blood sugar and promoting weight loss.  

There are several categories of GLP-1 weight loss medications:

• Semaglutide  

• Exenatide

• Liraglutide

• Dulaglutide

• Lixisenatide

• Tirzepatide — a dual GLP-1/GIP medication.

Although these medications share certain characteristics, they differ in dosing schedules, approved indications, clinical outcomes, and safety considerations. Healthcare providers should distinguish between medications approved for diabetes management and those specifically indicated for chronic weight management.

Evaluating Appropriate Candidates for Treatment

GLP-1-based medications are not appropriate for every patient seeking weight loss.  

In general, GLP-1 weight loss medications can be considered for patients with:

• BMI of 30 kg/m² or greater

• BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, or cardiovascular disease.

Providers should also assess patients for:

• Weight trajectory

• Existing metabolic, cardiovascular, gastrointestinal, and endocrine conditions

• Current medications

• History of pancreatitis, gallbladder disease, or significant gastrointestinal disorders

• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

• Pregnancy status, reproductive plans, and potential nutritional concerns

• Previous weight-management interventions

• Patient expectations

These assessments aren’t just important for selecting an appropriate medication. They also help establish reasonable patient expectations and combat misinformation from popular media.  

Initiating Treatment and Managing Doses

Because these medications are associated with fast results, patients often view dosage increases as a race to the top. That can quickly lead to gastrointestinal problems and other complications.  

Providers should not accelerate dosing simply because a patient wants faster weight loss—and that’s where setting realistic expectations becomes key.  

During initiation, healthcare professionals should explain:

1. How and when to administer the medication.

2. The purpose of the starting dose.

3. The expected timing of dose increases.

4. What to do if a dose is missed.

5. Which symptoms warrant contacting the healthcare team.

6. How to store and handle the medication safely.

Patients should also be cautioned against independently changing doses or combining GLP-1-based medications without clinical direction.

Recognizing and Managing Adverse Effects

Gastrointestinal symptoms are among the most common side effects associated with GLP-1 receptor agonists. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite may occur, particularly during dose escalation.

More serious concerns include:

• Acute pancreatitis: Persistent, severe abdominal pain, particularly when radiating to the back, requires prompt evaluation.

• Gallbladder disease: Rapid weight loss may be associated with gallstones and other gallbladder complications. New right upper-quadrant pain, fever, or jaundice warrants assessment.

• Hypoglycemia: The risk may increase when GLP-1-based medications are used with insulin or insulin secretagogues such as sulfonylureas.

• Delayed gastric emptying: This effect may be clinically important in patients with significant gastrointestinal motility disorders.

Addressing Medication Interactions and Special Populations

GLP-1-based therapies require careful consideration of the patient’s broader medication regimen and clinical circumstances.

Diabetes

Patients with diabetes may need adjustments to insulin or sulfonylurea therapy as glucose levels improve. Clinicians should monitor for hypoglycemia and ensure patients understand how to recognize and manage it.

Digestion

Delayed gastric emptying may affect the absorption of some oral medications. Providers should review oral therapies individually rather than assuming that every medication will be affected in the same way.

Pregnancy

Weight-loss treatment is not appropriate during pregnancy, and clinicians should consult the specific prescribing information when counseling patients who are pregnant, planning pregnancy, or capable of becoming pregnant.  

Long-Term Treatment and Weight Regain

One of the most important considerations in GLP-1 weight loss management is that obesity is a chronic condition. Patients may assume that medication can be stopped once a desired weight is achieved. However, discontinuation frequently leads to weight regain.

Providers should discuss treatment duration early in the prescribing process. Conversations may include:

• The possibility of ongoing pharmacotherapy  

• Anticipated benefits and potential adverse effects

• Insurance coverage, medication affordability, and access

• Strategies for maintaining nutritional and physical activity habits

• Monitoring plans if treatment is interrupted or discontinued

• Alternative treatment options  

If discontinuation becomes necessary, patients should receive an individualized follow-up plan. Abruptly stopping medication without considering the patient’s diabetes status, weight trajectory, and other health conditions may create avoidable clinical challenges.

Supporting Patient-Centered Weight Management

Effective counseling is central to successful GLP-1 weight loss care. Patients may experience stigma, unrealistic expectations, or frustration if their weight changes more slowly than anticipated.  

Healthcare providers can help by framing obesity as a complex chronic disease influenced by biological, environmental, behavioral, and social factors.

Treatment goals should extend beyond weight alone. Improvements in mobility, blood pressure, glucose control, sleep, cardiovascular risk, and daily functioning may be meaningful indicators of progress.

Shared decision-making allows patients to participate actively in selecting treatment strategies. Clinicians should explain expected benefits, uncertainties, risks, costs, and alternatives in language the patient can understand.

Finally, healthcare providers should follow up with patients regularly. A multidisciplinary approach may be particularly beneficial for patients with multiple chronic conditions or complex nutritional and psychosocial needs.

Safe and Effective Management of GLP-1 Weight Loss

GLP-1-weight loss medications will continue to be popular options for patients with obesity and diabetes challenges. Healthcare providers will need to stay on top of new information, medications, and best practices as new research becomes available.

Premiere is committed to keeping doctors, nurses, and allied health workers on the leading edge of GLP-1 developments. Courses like Expanding the GLP Landscape deliver insights about how to administer these medications safely and the side effects to consider.  

All of Premiere’s award-winning courses are created by industry experts and make it easy for busy healthcare workers to build their careers and meet their professional obligations.  

FAQs

Which GLP-1 is best for weight loss?

Semaglutide, exenatide, liraglutide, dulaglutide, lixisenatide, and tirzepatide medications all mimic GLP hormone responses in the gastrointestinal tract. These overlap with insulin and diabetes-related complications, and doctors should evaluate each patient individually to determine which medication is most appropriate.

What is the downside of taking GLP-1?

GLP-1 weight loss medications can also come with significant side effects. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite may all occur during initiation and dosage increases. GLP-1s can also cause acute pancreatitis, gallbladder disease, and hypoglycemia.

Is it safe to stop taking GLP-1 during pregnancy?

Yes. Patients should stop taking GLP-1 medications 30-60 days before attempting to get pregnant to protect fetal health.  

What medications negatively interact with GLP-1?

Diabetes medications, including insulin, may produce serious side effects when combined with GLP-1 medications. GLP-1 weight loss drugs may also slow absorption of oral medications, and healthcare providers will need to evaluate each pharmaceutical individually.  

At what weight should patients consider GLP-1?

Patients are eligible for GLP-1 weight loss medications when they have a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater and at least one weight-related comorbidity.